Bringing pharmaceutical manufacturing back to US has bipartisan political support, especially after Covid-19 exposed America’s dependence on overseas drug supply chains
US President Donald Trump on Wednesday announced that imported generic medicines will remain exempt from tariffs for the next two years, but warned that they could face duties of up to 100 per cent initially and 200 per cent later if drugmakers continue to manufacture overseas instead of shifting production to the US.
The announcement is part of Trump’s broader push to revive domestic manufacturing and reduce America’s dependence on imported pharmaceuticals. For India, however, the proposal has far-reaching implications. The country is one of the world’s largest suppliers of generic medicines and counts the US as its biggest export market for pharmaceuticals.
What Exactly Did Trump Say?
Trump said generic medicines will face 0 per cent tariffs for the next two years, giving pharmaceutical companies time to move manufacturing to the United States. After that, imports could face tariffs starting at 100 per cent and eventually rising to 200 per cent.
The proposal is aimed at encouraging companies to manufacture drugs in the US rather than importing them from countries such as India and China. However, the plan is yet to go through the formal policy and rule-making process, meaning details could still change.
Why Is India The Biggest Stakeholder?
India is often called the “pharmacy of the world” because of its massive generic drug manufacturing industry.
The US is India’s largest pharmaceutical export destination. India supplies a significant share of generic medicines consumed in the US, ranging from antibiotics and diabetes medicines to cancer drugs. Indian companies have also built their business models around exporting affordable medicines manufactured in India.
If steep tariffs are eventually imposed, these exports could become significantly more expensive and less competitive in the US market.
Why The Two-Year Relief?
A sudden tariff would have disrupted drug supplies and increased healthcare costs in the US almost immediately.
The two-year exemption appears designed to give pharmaceutical companies time to relocate manufacturing, avoid shortages of essential medicines, and allow the US to expand domestic production capacity before imposing high import duties.
Experts quoted by CNN say moving pharmaceutical manufacturing is far more complex than relocating production in sectors like electronics or apparel because it requires regulatory approvals, inspections and new supply chains.
Which Indian Companies Could Be Affected?
Several leading Indian pharmaceutical companies derive a substantial portion of their revenue from the US market. Among those with significant exposure are Sun Pharma, Dr. Reddy’s Laboratories, Aurobindo Pharma, Lupin, Zydus Lifesciences, Cipla, Glenmark Pharmaceuticals, and Torrent Pharmaceuticals.
The impact, however, will differ.
Companies that already own manufacturing facilities in the US or have diversified production across multiple countries may be better positioned than firms that primarily export medicines manufactured in India.
Will Medicines Become Costlier In US?
Potentially, yes.
Generic medicines account for the overwhelming majority of prescriptions filled in the US because they are much cheaper than branded drugs.
If import costs rise sharply due to tariffs, drug manufacturers could pass some of the additional cost to distributors and healthcare providers. Insurance companies may face higher reimbursement costs and patients could ultimately pay more for medicines.
Analysts speaking to Reuters also warn that reduced competition could worsen existing drug shortages if companies decide exporting to the US is no longer commercially viable.
Could Indian Pharma Companies Shift Manufacturing To US?
Some already have. Several major Indian drugmakers operate manufacturing facilities in the United States or have acquired American pharmaceutical plants over the years.
However, expanding production significantly would require fresh investments running into hundreds of millions of dollars, hiring skilled workers, meeting stringent US FDA approvals, and building new supply chains. For smaller companies, such a shift may not be financially feasible.
Can India Negotiate An Exemption?
There is no surety of that, Pharmaceutical trade is expected to feature prominently in future India-US trade discussions.
India may seek exemptions for essential medicines, lower tariffs for trusted pharmaceutical suppliers, longer transition periods, and sector-specific arrangements under a broader bilateral trade agreement.
Whether Washington agrees will depend on the final shape of Trump’s trade policy and negotiations between the two countries.
Genuine Policy Shift Or Negotiating Tactic?
It could be both.
Trump has frequently used tariff announcements as leverage in trade negotiations. At the same time, bringing pharmaceutical manufacturing back to the US has bipartisan political support, especially after the Covid-19 pandemic exposed America’s dependence on overseas drug supply chains.
While the exact tariff rates and implementation timeline remain uncertain, the direction of policy is clear: the US wants more pharmaceutical manufacturing on its own soil.
What Does This Mean For India?
In the short term, there is little immediate disruption because generic medicines remain tariff-free for two years.
In the medium term, Indian pharmaceutical companies are likely to reassess their manufacturing strategies, with some accelerating investments in US production facilities.
However, in the long term, if tariffs as high as 200 per cent are eventually implemented, India’s pharmaceutical industry could face one of its biggest challenges in decades in its largest export market. Companies with global manufacturing footprints may adapt more easily, while smaller exporters could come under significant pressure.
For now, the announcement serves less as an immediate blow and more as a two-year warning that the global pharmaceutical supply chain could be reshaped in favour of American manufacturing.
Rewrite this article to make it 100% unique and SEO-friendly. Keep the same meaning, but change the wording and sentence structure. Make it engaging, informative, and natural for human readers